Fintel reports that on April 29, 2025, HC Wainwright & Co. initiated coverage of MicroStrategy (NasdaqGS:MSTR) with a Buy ...

Fintel reports that on April 30, 2025, HC Wainwright & Co. downgraded their outlook for SpringWorks Therapeutics ...

H.C. Wainwright has initiated coverage of Strategy (formerly Microstrategy (NASDAQ:MSTR)) with a Buy rating and a $480 price target, calling it "one of the most compelling public equity investments ...

The company has a "first-mover advantage" when it comes to investing in Bitcoin, and its decision to retain all of the ...

HC Wainwright currently has a “Neutral” rating and a $1.00 target price on the stock. The consensus estimate for Cytosorbents’ current full-year earnings is ($0.30) per share.

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced its participation in the H.C. Wainwright ...

On Thursday, H.C. Wainwright analyst Mitchell Kapoor reaffirmed a Buy rating and a $2.00 price target for Century Therapeutics (NASDAQ:IPSC), representing significant upside from the current price ...

Bit Digital, a global platform for high-performance computing (HPC) infrastructure and digital asset mining company, has ...

HC Wainwright currently has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for Milestone Pharmaceuticals’ current full-year earnings is ($0.62) per share.

Detailed price information for Olema Pharmaceuticals Inc (OLMA-Q) from The Globe and Mail including charting and trades.

H.C. Wainwright reiterates a Buy rating and $12 price target on shares of Orchestra BioMed (OBIO) after the company announced that the Food and ...

Novocure (NVCR) recognized first non-small cell lung cancer revenues ahead of schedule, with 92 Optune Lua prescriptions for NSCLC received in ...